AMSBIO has announced the availability of highly modified synthetic 5-prime capped mRNA products for reprogramming of human cells. These new ready-to-use products provide a simple, safe non-integrating methodology for reprogramming cell fate based on the administration of synthetic modified mRNA that greatly increases efficiency whilst reducing the innate antiviral response of viral protocols.
Clinical applications of induced pluripotent stem cells (iPSCs) have traditionally been limited [1] by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically applicable cell types are not possible by viral methods.
Today AMSBIO can provide ready-to-use highly modified mRNAs including Kfl4, c-Myc, Oct4, Sox2, LIN28 mRNA, and eGFP control, in customised formats for your research. These proven synthetic adaptations of 5-prime, 3-prime and internal mRNA structures enable reprogramming of multiple human cell types to pluripotency with conversion efficiencies that greatly surpass established methods. Furthermore this same technology can be used to efficiently direct the differentiation of mRNA-induced pluripotent stem cells into terminally differentiated cells and can be employed as an alternative to DNA-based gene therapy [2].
This technology represents a safe, non-mutagenic and efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, tissue-engineering and regenerative medicine.
Drawing upon over 20 years experience - AMSBIO is able to offers a complete cell reprogramming service, from initial consultancy, synthesis of modified DNA, plasmid cloning, full DNA sequencing documentation, PCR amplification of inserts and characterization with subsequent RNA synthesis by in vitro transcription.
For further information please visit http://www.amsbio.com/synthetic-mRNA-directed-stem-cell-differentiation.aspx or contact AMSBIO on +44-1235-828200 / +1-949-768-8365 or email info@amsbio.com
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading international provider of unique & innovative products & custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification & stem cell biology.
1. Warren, E. A. (2010). Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modifed mRNA. Cell Stem Cell, 7, 618-630.
2. Kormann M. S. (2011) Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. Feb;29(2): 154-7.
Worldwide HQ
AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
中文
